HQL · abrdn Life Sciences Investors
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Asset Management — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HQL
this stock
abrdn Life Sciences Investors
|
$591.13M | +18.2% | — | — | 0.2% |
|
BLK
BlackRock, Inc.
|
$351.47B | +1.4% | +16.2% | 27.2 | 0.6% |
|
BX
Blackstone Inc.
|
$95.14B | -15.1% | +9.2% | 32.8 | 3.2% |
|
BN
BROOKFIELD Corp /ON/
|
$93.95B | -8.8% | — | — | 0.7% |
|
KKR
KKR & Co. Inc.
|
$90.67B | -22.0% | -11.0% | — | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HQL | -2.7% | -4.1% | +16.2% | -4.1% | +18.2% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -0.3% | -1.8% | +9.8% | -1.8% | +11.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.